UB Paderborn / Katalog / Suche / in CDI

1 – 20 von 20

Sortiert nach

Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer

Journal of clinical oncology, 2007-05, Vol.25 (15), p.2086-2092

2007

Volltextzugriff (PDF)

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

The New England journal of medicine, 2016-11, Vol.375 (19), p.1823-1833

2016

Volltextzugriff (PDF)

Standard Versus Intensified Chemotherapy With Granulocyte Colony-Stimulating Factor Support in Small-Cell Lung Cancer: A Prospective European Organization for Research and Treatment of Cancer–Lung Cancer Group Phase III Trial—08923

Journal of clinical oncology, 2002-10, Vol.20 (19), p.3947-3955

2002

Volltextzugriff (PDF)

European Organization for Research and Treatment of Cancer (EORTC) 08957 Phase II Study of Topotecan in Combination with Cisplatin as Second-Line Treatment of Refractory and Sensitive Small Cell Lung Cancer

Clinical cancer research, 2003-01, Vol.9 (1), p.143-150

2003

Volltextzugriff (PDF)

Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial

Journal of clinical oncology, 2017-04, Vol.35 (12), p.1281-1287

2017

Volltextzugriff (PDF)

Predictive and Prognostic Significance of Neuron-specific Enolase (NSE) in Non-small Cell Lung Cancer

Anticancer research, 2008-01, Vol.28 (1B), p.507-513

2008

Volltextzugriff (PDF)

Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial

Journal of clinical oncology, 2024-01, Vol.42 (2), p.180

2024

Volltextzugriff (PDF)

Multifactorial Central Nervous System Recurrence Susceptibility in Patients With HER2-Positive Breast Cancer: Epidemiological and Clinical Data From a Population-Based Cancer Registry Study

Cancer, 2011-05, Vol.117 (9), p.1837-1846

2011

Volltextzugriff (PDF)

Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer

Cancer, 2006-12, Vol.107 (12), p.2842-2849

2006

Volltextzugriff (PDF)

Concurrent Chemoradiation with Concomitant Boost in Locally Advanced Rectal Cancer: A Phase II Study

Anticancer research, 2016-08, Vol.36 (8), p.4081

2016

Volltextzugriff (PDF)

Long-term results of preoperative 5-fluorouracil-oxaliplatin chemoradiation therapy in locally advanced rectal cancer

Anticancer research, 2013-02, Vol.33 (2), p.725-730

2013

Volltextzugriff (PDF)

Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

Journal of clinical oncology, 1996-03, Vol.14 (3), p.814-820

1996

Volltextzugriff (PDF)

Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO‐P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non‐Hodgkin lymphoma

Cancer, 2005-05, Vol.103 (10), p.2109-2117

2005

Volltextzugriff (PDF)

Study of pretreatment serum levels of HER‐2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma

Cancer, 2001-10, Vol.92 (7), p.1896-1904

2001

Volltextzugriff (PDF)

Stage I-II melanoma: the value of metastatic work-up

Oncology, 1987, Vol.44 (2), p.87

1987

Volltextzugriff (PDF)

Hypercoagulable state induced by cytostatic drugs in stage ii breast cancer patients

Cancer, 1986-09, Vol.58 (5), p.1032-1036

1986

Volltextzugriff (PDF)

Control of refractory, chemotherapy-induced emesis with the serotonin antagonist ondansetron (GR38032F)

Oncology, 1991, Vol.48 (5), p.403

1991

Volltextzugriff (PDF)

Survival of patients with relapsing breast cancer: analysis of 302 patients

Oncology, 1986, Vol.43 (5), p.278

1986

Volltextzugriff (PDF)

1 – 20 von 20

Suche als RSS-Feed

Aktive Filter

KollektionSingle Journals

ThemaAdult

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(16)

Publikationsform

Artikel
(20)

Sprache

Englisch
(20)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Humans
(20)
Middle Aged
(19)
Aged
(18)
Life Sciences & Biomedicine
(18)
Science & Technology
(18)
Female
(17)
Oncology
(17)
Male
(14)
Biological And Medical Sciences
(12)
Medical Sciences
(12)
Lung Neoplasms - Drug Therapy
(9)
Tumors
(9)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(7)
Aged, 80 And Over
(6)
Chemotherapy
(6)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(5)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(5)
Disease-Free Survival
(5)
Pneumology
(5)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial

Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer

Pemetrexed Versus Pemetrexed and Carboplatin As Second-Line Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the GOIRC 02-2006 Randomized Phase II Study and Pooled Analysis With the NVALT7 Trial

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Standard Versus Intensified Chemotherapy With Granulocyte Colony-Stimulating Factor Support in Small-Cell Lung Cancer: A Prospective European Organization for Research and Treatment of Cancer–Lung Cancer Group Phase III Trial—08923

European Organization for Research and Treatment of Cancer (EORTC) 08957 Phase II Study of Topotecan in Combination with Cisplatin as Second-Line Treatment of Refractory and Sensitive Small Cell Lung Cancer

Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial

Predictive and Prognostic Significance of Neuron-specific Enolase (NSE) in Non-small Cell Lung Cancer

Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial

Multifactorial Central Nervous System Recurrence Susceptibility in Patients With HER2-Positive Breast Cancer: Epidemiological and Clinical Data From a Population-Based Cancer Registry Study

Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer

Concurrent Chemoradiation with Concomitant Boost in Locally Advanced Rectal Cancer: A Phase II Study

Long-term results of preoperative 5-fluorouracil-oxaliplatin chemoradiation therapy in locally advanced rectal cancer

Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO‐P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non‐Hodgkin lymphoma

Study of pretreatment serum levels of HER‐2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma

Stage I-II melanoma: the value of metastatic work-up

Hypercoagulable state induced by cytostatic drugs in stage ii breast cancer patients

Control of refractory, chemotherapy-induced emesis with the serotonin antagonist ondansetron (GR38032F)

Survival of patients with relapsing breast cancer: analysis of 302 patients

Aktive Filter

Suchergebnisse filtern